Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant docetaxel + zoledronic acid + goserelin before radical prostatectomy for high-risk prostate cancer
ACTRN12607000082404Phase 2Not yet recruiting
- Sponsor
- Royal Melbourne Hospital
- Start
- Apr 2007
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, zoledronic acid and goserelin in prostate cancer (PCa), sponsored by Royal Melbourne Hospital. Primary endpoints: Safety and Tolerability. Planned start Apr 2007; status: not yet recruiting.
02
Drugs
docetaxelzoledronic acidgoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12607000082404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000082404.